OBJECTIVES:Soluble CD14 (sCD14) is a monocyte activation marker associated with increased mortality in HIV infection. We assessed 48-week changes in sCD14 and other inflammatory biomarkers in virologically suppressed, HIV-infected women switching to raltegravir (RAL) from a protease inhibitor (PI) ornonnucleoside reverse transcriptase inhibitor (NNRTI). METHODS:HIV-infected women with central adiposity and HIV-1 RNA <; 50 HIV-1 RNA copies/mL continued their thymidine-sparing nucleoside reverse transcriptase inhibitor (NRTI) backbone and were randomized to switch to open-label RAL at week 0 (immediate) or 24 (delayed). In an exploratory analysis, inflammatory biomarkers were measured on stored fasting plasma. RESULTS: Of the 37 evaluable subjects, 78% were non-White; the median age was 43 years, the median body mass index (BMI) was 32 kg/m(2) and the median CD4 count was 558 cells/μL. At baseline, biomarker values were similar between groups. After 24 weeks, median sCD14 significantly declined in subjects switching to RAL [-21% (P < 0.001) vs. PI/NNRTI -5% (P = 0.49); between-group P < 0.01]. After 48 weeks, immediate-switch subjects maintained this decline and delayed-switch subjects experienced a similar decline following the switch to RAL (-10%; within-group P < 0.01). Immediate-switch subjects also experienced an initial increase in tumour necrosis factor (TNF)-α that was neither maintained after 48 weeks nor seen in delayed-switch subjects. After adjustment for multiple testing, only declines in sCD14 remained significant. CONCLUSIONS: In this randomized trial of women with central adiposity, a switch to RAL from a PI or NNRTI was associated with a statistically significant decline in sCD14. Further studies are needed to determine whether integrase inhibitors have improved monocyte activation profiles compared with PIs and/or NNRTIs, and whether measured differences between antiretroviral agents translate to demonstrable clinical benefit.
RCT Entities:
OBJECTIVES: Soluble CD14 (sCD14) is a monocyte activation marker associated with increased mortality in HIV infection. We assessed 48-week changes in sCD14 and other inflammatory biomarkers in virologically suppressed, HIV-infectedwomen switching to raltegravir (RAL) from a protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI). METHODS:HIV-infectedwomen with central adiposity and HIV-1 RNA < 50 HIV-1 RNA copies/mL continued their thymidine-sparing nucleoside reverse transcriptase inhibitor (NRTI) backbone and were randomized to switch to open-label RAL at week 0 (immediate) or 24 (delayed). In an exploratory analysis, inflammatory biomarkers were measured on stored fasting plasma. RESULTS: Of the 37 evaluable subjects, 78% were non-White; the median age was 43 years, the median body mass index (BMI) was 32 kg/m(2) and the median CD4 count was 558 cells/μL. At baseline, biomarker values were similar between groups. After 24 weeks, median sCD14 significantly declined in subjects switching to RAL [-21% (P < 0.001) vs. PI/NNRTI -5% (P = 0.49); between-group P < 0.01]. After 48 weeks, immediate-switch subjects maintained this decline and delayed-switch subjects experienced a similar decline following the switch to RAL (-10%; within-group P < 0.01). Immediate-switch subjects also experienced an initial increase in tumour necrosis factor (TNF)-α that was neither maintained after 48 weeks nor seen in delayed-switch subjects. After adjustment for multiple testing, only declines in sCD14 remained significant. CONCLUSIONS: In this randomized trial of women with central adiposity, a switch to RAL from a PI or NNRTI was associated with a statistically significant decline in sCD14. Further studies are needed to determine whether integrase inhibitors have improved monocyte activation profiles compared with PIs and/or NNRTIs, and whether measured differences between antiretroviral agents translate to demonstrable clinical benefit.
Authors: Tricia H Burdo; Allison Weiffenbach; Steven P Woods; Scott Letendre; Ronald J Ellis; Kenneth C Williams Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Gema Méndez-Lagares; M Concepción Romero-Sánchez; Ezequiel Ruiz-Mateos; Miguel Genebat; Sara Ferrando-Martínez; María Á Muñoz-Fernández; Yolanda M Pacheco; Manuel Leal Journal: J Infect Dis Date: 2013-01-15 Impact factor: 5.226
Authors: I W Manner; M Baekken; D Kvale; O Oektedalen; M Pedersen; S D Nielsen; P Nowak; I Os; M Trøseid Journal: HIV Med Date: 2013-01-17 Impact factor: 3.180
Authors: John R Koethe; Kevin Dee; Aihua Bian; Ayumi Shintani; Megan Turner; Sally Bebawy; Timothy R Sterling; Todd Hulgan Journal: AIDS Res Hum Retroviruses Date: 2013-04-11 Impact factor: 2.205
Authors: Kristine B Patterson; Heather A Prince; Trenton Stevens; Nicholas J Shaheen; Evan S Dellon; Ryan D Madanick; Steven Jennings; Myron S Cohen; Angela D M Kashuba Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Hiroyu Hatano; Matthew C Strain; Rebecca Scherzer; Peter Bacchetti; Deborah Wentworth; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; James D Neaton; Russell P Tracy; Priscilla Y Hsue; Douglas D Richman; Steven G Deeks Journal: J Infect Dis Date: 2013-08-23 Impact factor: 5.226
Authors: Genevieve E Martin; Maelenn Gouillou; Anna C Hearps; Thomas A Angelovich; Allen C Cheng; Fiona Lynch; Wan-Jung Cheng; Geza Paukovics; Clovis S Palmer; Richard M Novak; Anthony Jaworowski; Alan L Landay; Suzanne M Crowe Journal: PLoS One Date: 2013-01-24 Impact factor: 3.240
Authors: Netanya S Utay; Douglas W Kitch; Eunice Yeh; Carl J Fichtenbaum; Michael M Lederman; Jacob D Estes; Claire Deleage; Clara Magyar; Scott D Nelson; Karen L Klingman; Barbara Bastow; Amneris E Luque; Grace A McComsey; Daniel C Douek; Judith S Currier; Jordan E Lake Journal: J Infect Dis Date: 2018-05-05 Impact factor: 5.226
Authors: Theodoros Kelesidis; Thuy Tien T Tran; James H Stein; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Robert Murphy; Otto O Yang; Judith S Currier; Grace A McComsey Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: Archana Asundi; Yvonne Robles; Tyler Starr; Alan Landay; Jennifer Kinslow; Joshua Ladner; Laura White; Rebeca M Plank; Kathleen Melbourne; Daniel Weisholtz; Monica Bennett; Hong Pan; Emily Stern; Alexander Lin; Daniel R Kuritzkes; Nina H Lin Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: Corrilynn O Hileman; Bruce Kinley; Valeska Scharen-Guivel; Kathy Melbourne; Javier Szwarcberg; Janet Robinson; Michael M Lederman; Grace A Mccomsey Journal: J Infect Dis Date: 2015-01-12 Impact factor: 5.226
Authors: Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Vidya Mave; Kristine M Erlandson; Nikhil Gupte; Ashwin Balagopal; David M Asmuth; Thomas B Campbell; Laura Smeaton; Nagalingeswaran Kumarasamy; James Hakim; Breno Santos; Cynthia Riviere; Mina C Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Srikanth Tripathy; Noluthando Mwelase; Sima Berendes; Bruno B Andrade; David L Thomas; Robert C Bollinger; Amita Gupta Journal: J Infect Dis Date: 2016-03-08 Impact factor: 5.226
Authors: Sara E Looby; Amy Kantor; Tricia H Burdo; Judith S Currier; Carl J Fichtenbaum; Edgar T Overton; Judith A Aberg; Carlos D Malvestutto; Gerald S Bloomfield; Kristine M Erlandson; Michelle Cespedes; Esper G Kallas; Mar Masiá; Alice C Thornton; Mandy D Smith; Jacqueline M Flynn; Emma M Kileel; Evelynne Fulda; Kathleen V Fitch; Michael T Lu; Pamela S Douglas; Steven K Grinspoon; Heather J Ribaudo; Markella V Zanni Journal: Clin Infect Dis Date: 2022-10-12 Impact factor: 20.999